The AP1AR Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T-lymphocyte cell line. This product provides a loss-of-function model for the AP1AR gene, encoding an adaptor protein that bridges clathrin and the AP-1 complex at the trans-Golgi network. The polyclonal nature of the knockout pool preserves genetic heterogeneity, enabling robust population-level analyses of AP1AR-dependent phenotypes without clonal isolation artifacts.
Jurkat cells are a widely used model in immunology and cancer research, originally established from the peripheral blood of a 14-year-old male with acute T-cell leukemia. As a T-lymphocyte line, Jurkat cells recapitulate key aspects of adaptive immunity, particularly T-cell receptor (TCR) signaling. Their leukemic origin additionally makes them a relevant system for investigating oncogenic mechanisms and therapeutic vulnerabilities. The combination of a well-characterized signaling network and ease of genetic manipulation positions Jurkat cells as an ideal host for dissecting gene function in lymphocyte biology.
AP1AR functions as a clathrin-associated adaptor that links the clathrin triskelion to the AP-1 complex at the trans-Golgi network, facilitating the formation of clathrin-coated vesicles destined for endosomes. This process is regulated upstream by ARF1 GTPase and coordinated with cargo sorting signals recognized by AP-1 subunits such as AP1G1. Disruption of AP1AR interferes with the recruitment of the AP-1 complex and clathrin heavy chain to membranes, impairing cargo receptor sorting and subsequent vesicle budding. Downstream consequences include altered intracellular trafficking of receptors like the mannose-6-phosphate receptor and mislocalization of lysosomal enzymes, highlighting AP1AR’s centrality in Golgi-to-endosome transport.
In Jurkat T cells, the knockout of AP1AR is expected to perturb clathrin-mediated endocytosis and intracellular protein trafficking, processes critical for TCR signal modulation and surface receptor homeostasis. Given that Jurkat cells rely on precise receptor localization for activation and effector functions, AP1AR loss may compromise T-cell activation thresholds, cytokine secretion, or cytotoxic responses. Moreover, given the leukemic background, this model offers a platform to investigate how trafficking dysregulation contributes to malignant transformation and immune evasion in T-cell malignancies.
This AP1AR knockout cell pool supports a broad range of experimental applications, including dissection of adaptor protein contributions to lymphocyte trafficking, screening for trafficking-dependent signaling defects, and validation of protein interaction networks. Representative assays include western blotting of key trafficking proteins, immunofluorescence to assess AP-1 complex localization, flow cytometry for surface receptor profiling, and co-immunoprecipitation of AP1AR with clathrin or AP-1 subunits. Transferrin uptake and live-cell imaging further enable kinetic studies of endocytosis and vesicle dynamics. For additional information, please contact Ascent Research.
